WallFlex™ Biliary RX Fully Covered Stent System RMV

Now indicated in the U.S. for benign biliary strictures secondary to chronic pancreatitis with indwell up to 12 months.

This expanded indication represents a significant clinical milestone in achieving optimal treatment strategies for chronic pancreatitis patients suffering from bile duct strictures. The unique stent design, with an integrated retrieval loop and Permalume™ covering, allows for removal up to 12 months post-deployment, unlike most plastic stents that may require replacement an average of 5 times per year*.

Designed for removal up to 12 months post-placement
Initial placement of a fully covered self-expanding metal stent for benign biliary strictures secondary to chronic pancreatitis may help to avoid the cost of multiple ERCP with stent placement procedures, potentially saving the hospital system at least $3,820 per procedure.

<table>
<thead>
<tr>
<th>CPT® Code</th>
<th>Description</th>
<th>2014 Medicare Geometric Mean Cost – Outpatient **</th>
</tr>
</thead>
<tbody>
<tr>
<td>43274</td>
<td>Endoscopic retrograde cholangiopancreatography (ERCP); with placement of endoscopic stent into biliary or pancreatic duct, including pre- and post-dilation and guide wire passage, when performed, including sphincterotomy, when performed, each stent</td>
<td>$3,820</td>
</tr>
</tbody>
</table>

**Source: Medicare’s CY 2016 OPPS Cost Statistic File**

CPT Copyright 2015 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Restrictions Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

The potential economic impact identified in this case only takes into account procedural costs avoided and does not take into account reimbursement.

The safety and effectiveness of this device for use in the vascular system has not been established.